Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (Nasdaq:DYN) announced participation in several investor conferences focused on healthcare in May and June 2026.
Management will join fireside chats at the RBC Capital Markets Global Healthcare Conference on May 20 and the Jefferies Global Healthcare Conference on June 3 in New York, plus investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami.
Live webcasts and 90-day replays of the fireside chats will be available in the Investors & Media section of Dyne’s website.
Dyne Therapeutics (Nasdaq:DYN) reported Q1 2026 results and key pipeline milestones in DMD and DM1.
Cash, cash equivalents and marketable securities were $972.2 million, expected to fund operations into Q1 2028. Dyne advanced z-rostudirsen toward a Q2 2026 BLA and Q1 2027 potential launch, and z-basivarsen toward Phase 3 and a possible Q1 2028 launch.
Dyne Therapeutics (NASDAQ: DYN) will present preclinical data at ASGCT May 11-15, 2026 showing the FORCE platform crosses the blood-brain barrier and enables robust CNS MAPT RNA knockdown in mice and nonhuman primates.
Two conjugates were tested: Conjugate 1 (clinically validated FORCE Fab) and Conjugate 2 (Fab optimized for CNS). Conjugate 2 achieved approximately 75% MAPT RNA knockdown with widespread brain delivery; subcutaneous dosing in mice matched intravenous reductions. Slides will be posted at the presentation start.
Dyne Therapeutics (Nasdaq: DYN) granted inducement equity awards to 18 new employees on April 23, 2026, under Nasdaq Listing Rule 5635(c)(4).
The awards include non‑statutory stock options to purchase an aggregate of 320,900 shares at the closing price on April 21, 2026, and restricted stock units for an aggregate of 102,100 shares. Options have a 10‑year term; options vest over four years (25% after one year, then quarterly) and RSUs vest in four equal annual installments, all subject to continued service and the 2024 Inducement Stock Incentive Plan.
Dyne Therapeutics (Nasdaq: DYN) will present three posters at the AMCP 2026 Annual Conference in Nashville, April 13-16, 2026, covering Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Presentations include DELIVER and ACHIEVE trial data, a DM1 health insurance literacy study developed with Myotonic Dystrophy Foundation, and a payer-focused symposium on April 14, 12:00–1:30 p.m. CT. Dyne said these activities aim to inform managed care access decisions ahead of potential DMD and DM1 launches.
Dyne Therapeutics (Nasdaq: DYN) initiated the Phase 3 HARMONIA trial of z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1).
The global, randomized, double-blind trial will enroll approximately 150 participants (age 16+) randomized 1:1 to 6.8 mg/kg IV every eight weeks or placebo for a 48-week treatment period. The primary endpoint is change in the five times sit to stand (5xSTS) at week 49. Secondary and exploratory measures cover muscle function, CNS domains, and patient- and clinician-reported outcomes. The protocol is aligned with the FDA and is intended to support conversion to traditional U.S. approval and ex-U.S. marketing applications.
Dyne Therapeutics (Nasdaq: DYN) reported new 24-month cardiopulmonary analyses from the Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251) in exon 51 skip–amenable Duchenne muscular dystrophy. Improvements were seen versus expected natural-history declines in FVC%p, circumferential strain, and left ventricular ejection fraction at 24 months. Safety data from 86 participants followed up to 36 months showed mostly mild-to-moderate related TEAEs, chiefly pyrexia and headache, and no related serious TEAEs in the reported cohort. Findings were presented as a late-breaking poster at the 2026 MDA Clinical & Scientific Conference.
Dyne Therapeutics (Nasdaq: DYN) reported Q4 and full-year 2025 results and program updates on March 2, 2026. Key clinical milestones include positive registrational REC topline results for z-rostudirsen (dystrophin 5.46% of normal at six months) and planned BLA submission in Q2 2026.
Cash totaled $1.1 billion at year-end, with the company reaffirming runway into Q1 2028. Enrollment and Phase 3 plans for z-basivarsen (DM1) and additional DMD exon programs are underway.
Dyne Therapeutics (Nasdaq: DYN) said management will participate in several investor conferences in March 2026, including TD Cowen (fireside chat Mar 4), Jefferies Biotech on the Beach (meetings Mar 10–11) and Stifel Virtual CNS Forum (fireside chat Mar 17).
Live webcasts of each fireside chat will be available on Dyne's Investors & Media site and replays accessible for 90 days.
Dyne Therapeutics (Nasdaq: DYN) will present five abstracts, including three oral talks, at the 2026 MDA Clinical & Scientific Conference March 8-11, 2026, covering Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease.
Highlights include late-breaking DELIVER cardiopulmonary function data for z-rostudirsen (DYNE-251), a Phase 3 design for z-basivarsen (DYNE-101) in DM1, and preclinical DYNE-401 Pompe data; posters and slides will be posted on the company website in sync with the conference.